|
Post by mnkdfann on Dec 19, 2018 20:34:58 GMT -5
Is it even remotely possible that big news (Brazil approval, filings in Canada and Mexico) is coming, that will send the shares up big time, and this filing is in advance of that? To be prepared to strike on a day or two when the iron is hot?
Do companies ever do that?
|
|
|
Zacks
Dec 19, 2018 20:31:41 GMT -5
Post by mnkdfann on Dec 19, 2018 20:31:41 GMT -5
I actually don’t think the company paid for the ad on zacks. I am 99.99 percent certain it is the pipe funding underwriter leerink (sp) I feel sorry for Zacks analysts Brian Marckx, CFA and Anita Dushyanth, PhD who wrote the ad. Assuming the analyst disclosure is true ("Zacks SCR Analysts hereby certify that the view expressed in this research report or blog article accurately reflect the personal views of the analyst about the subject securities and issuers"), they must feel dirty and used this evening. Well, I suppose it is a part of their job.
|
|
|
Post by mnkdfann on Dec 19, 2018 19:30:34 GMT -5
Now we know why the company employed Zacks to pump the stock. See new shelf offering Sure looks that way. And boy do I sure look sharp now, having seemingly predicted a share offering a few posts above.
|
|
|
Post by mnkdfann on Dec 19, 2018 18:53:07 GMT -5
Aged, I posted it. I looked at it. Sorry, so you did. I am surprised nobody commented on it, Afrezza is at least twice as expensive as any of the RAAs. IIRC, there was a similar price chart in last year's SOC document. I'm nearly certain, as I was just looking at it yesterday.
|
|
|
Post by mnkdfann on Dec 19, 2018 18:45:12 GMT -5
We finally got one of his highly touted catalysts! One of these days some of his self-proclaimed 'discerning' followers (one in particular) might figure out what his real game was.
|
|
|
Post by mnkdfann on Dec 19, 2018 18:41:56 GMT -5
The five stages, denial, anger, bargaining, depression and acceptance.
|
|
|
Post by mnkdfann on Dec 19, 2018 17:19:52 GMT -5
|
|
|
Post by mnkdfann on Dec 19, 2018 17:15:42 GMT -5
|
|
|
Post by mnkdfann on Dec 19, 2018 17:10:10 GMT -5
Everyone is saying the stock has tanked but I've checked the price 5 times and we're sitting in the green 🤨 I suspect you are looking at the 4 p.m. closing price, and not the after hours real time price.
|
|
|
Post by mnkdfann on Dec 19, 2018 16:17:23 GMT -5
I won't name names, but IIRC numerous experts on this forum swore Mike said we were free and clear of dilution.
|
|
|
Post by mnkdfann on Dec 19, 2018 11:16:07 GMT -5
Yes mnkdfann, but isn't it nice to know that going forward we will hear formally what we have been privy to anecdotally in regards to CGM use and Afrezza? If that's what you meant. I'm not sure what I said that confused you, what I meant is exactly what I said. That is (in response to what someone else wrote), there was in fact a lot about CGMs written in the SOC. Look for yourself. They are listed at least 24 times in the index (under several different headings, like continuous glucose monitoring, flash CGMs, JDRF CGM trials, etc.), and are discussed on at least 10 pages (especially around pages 81-88). I wasn't commenting on Afrezza at all (although I did subsequently ask a question concerning Afrezza of someone else).
|
|
|
Post by mnkdfann on Dec 19, 2018 0:38:43 GMT -5
As I recall not much was mentioned about CGM usage in SoC. However as their penatration grows and people start to better see the correlation between TIR and lower Hba1c w fewer hypos from a true real time management of diabetes Afrezza will most certainly have to become the clear choice imho. Actually, there was quite a bit about about CGMs in the SOC. But not in conjunction with Afrezza, if that's what you meant.
|
|
|
Post by mnkdfann on Dec 17, 2018 17:29:02 GMT -5
Thanks for posting that, but I would personally encourage everyone to look at the full document for themselves. Download the complete pdf and search for inhaled insulin. The second change you noted above is correct, but incomplete. They also added in the next paragraph: "Inhaled insulin is contraindicated in patients with chronic lung disease, such as asthma and chronic obstructive pulmonary disease, and is not recommended in patients who smoke or who recently stopped smoking. All patients require spirometry (FEV1) testing to identify potential lung disease prior to and after starting inhaled insulin therapy." Sorry if this sounds negative, but I don't see the overall fantastic improvements others do. The language was cleaned up a bit, some new information was added. But we're talking a handful of lines in a 204 page document. Will many prescribers really notice? Or even spot the minor changes? And it's not like the remainder of the document (describing other options) remained static. I suspect several of them also scored some improved language.
|
|
|
Post by mnkdfann on Dec 17, 2018 17:13:11 GMT -5
PHARMACOLOGIC THERAPY FOR TYPE 2 DIABETES Is there a mention of inhaled insulin in that flow-chart? (I don't see one, but I have bad eyes.)
|
|
|
Post by mnkdfann on Dec 16, 2018 15:56:09 GMT -5
On December 14, Brazil's ANVISA announced that registration of 17 models of glymeters devices used to measure blood sugar levels had their registration canceled because they did not reach the desired level of performance. "Anvisa canceled the registrations of 17 models of glymeters. The decision was taken to withdraw from the market only products that do not meet the international standard of performance described in ISO 15197: 2013." I'm not sure, but offhand (from the list the article contains, see below) it appears that many of those same devices are used in the U.S. Does the U.S. not require that those devices meet the same ISO standards? Freestyle Lite Strips - Blood Glucose Test Abbott 80146501707 Contour TS (Blood Glucose Meter) Bayer 80384380012 Contour TS (Blood Glucose Test Strip) Bayer 80384380008 Easy Thrueread (Glucose Monitoring System) HDI 80095080018 Family of Glucose Strips: Easy True Read / Sidekick - Glucose Reagent Strips HDI 80095080020 Injex Glucose Meter Sens N Injex 10160610062 Injex Sens N - Blood Glucose Test Strips Injex 10160610057 Onetouch Ultra Mini System Johnson & Jonhson 80145901138 Blood Glucose Metering System Onetouch Select Simple Johnson & Johnson 80145901388 Onetouch Ultra Reagent Strips Johnson & Johnson 80145900869 Onetouch Select Reagent Strips Johnson & Johnson 80145901261 True Read Glucose Test Strips Nipro 80788620009 Easy Glucose Meter Trueread Nipro 80788620006 Accu-Check Glucose Monitor (Photometer) Roche 81414021673 Accutrend Glucose Roche 10287410219 Accutrend Plus Roche 10287410740 Tensortip Glucose Meter Family VR Medical 80102511569
|
|